🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

107 results for “Eli Lilly Co.” Clear

  1. Placebo to match LY3540378

    Eli Lilly Co.

    Heart Failure with Preserved Ejection Fraction, Heart Failure

    phase 2 small molecule active

    1 trial

  2. Placebo to match LY3556050

    Eli Lilly Co.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial

  3. Placebo to match LY3848575

    Eli Lilly Co.

    Neuropathic Pain; Distal Sensory Polyneuropathy

    phase 2 small molecule active

    1 trial

  4. TIRZEPATIDE, TIRZEPATIDE, Placebo to match LY3298176, TIRZEPATIDE, IOHEXOL , TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE

    Eli Lilly Co.

    Chronic Kidney Disease, CKD, Obesity, Overweight, T2D, Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  5. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Nisotirotide, placebo to match LY, Tirzepatide

    Eli Lilly Co.

    Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  6. Verzenios 50 mg film-coated tablets, TAMOXIFEN

    Eli Lilly Co.

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  7. Verzenios 50 mg film-coated tablets, TEMOZOLOMIDE , IRINOTECAN , Abemaciclib, Abemaciclib

    Eli Lilly Co.

    Ewings Sarcoma

    phase 2 small molecule active

    1 trial

  8. A Phase 1 Study on the effects of LY3410738 (study drug) administered to Patients with Advanced Solid Tumors with IDH1 or IDH2 Mutations

    Eli Lilly Co.

    Patients with IDH1 R132, IDH2 R140 or IDH2 R172-mutant advanced solid tumor types, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma.

    phase 1 other active

    1 trial

  9. A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

    Eli Lilly Co.

    Advanced/metastatic solid tumor

    phase 1 other active

    1 trial

  10. A Single-Dose Pharmacokinetic Study of Eloralintide in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function

    Eli Lilly Co.

    Participants with Mild, Moderate, or Severe Hepatic Impairment and Participants with Normal Hepatic Function

    phase 1 other active

    1 trial

  11. A Single-Dose Pharmacokinetic Study of Lepodisiran in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function

    Eli Lilly Co.

    Normal Hepatic Function and Mild, Moderate, or Severe Hepatic Impairment

    phase 1 other active

    1 trial

  12. A Study of LY3200882 in Participants With Solid Tumors.

    Eli Lilly Co.

    Metastatic cancer, Solid Tumor

    phase 1 other active

    1 trial

  13. A Study of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment

    Eli Lilly Co.

    Healthy, Hepatic Insufficiency

    phase 1 other active

    1 trial

  14. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

    Eli Lilly Co.

    Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell Lung Cancer SMARCA4-Deficient Tumor

    phase 1 other active

    1 trial

  15. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    Eli Lilly Co.

    Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

    phase 1 other active

    1 trial

  16. A Study of LY4057996 in Healthy Participants and Participants with Type 1 and Type 2 Diabetes (YKAA)

    Eli Lilly Co.

    Healthy, Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

    phase 1 other active

    1 trial

  17. A Study of LY4175408 in Participants With Advanced or Metastatic Solid Tumors.

    Eli Lilly Co.

    Cancer

    phase 1 other active

    1 trial

  18. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    Eli Lilly Co.

    Breast Neoplasms Colorectal Neoplasms Prostate Neoplasm Endometrial Neoplasms Neoplasm Metastasis

    phase 1 other active

    1 trial

  19. A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants with Type 1 Diabetes Mellitus.

    Eli Lilly Co.

    Type 1 Diabetes Mellitus

    phase 1 other active

    1 trial

  20. A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

    Eli Lilly Co.

    Diabetes Mellitus

    phase 1 other active

    1 trial

  21. A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia

    Eli Lilly Co.

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  22. A study of LOXO-783 in Patients with PIK3CA H1047R-Mutant Advanced Breast Cancer and Other Solid Tumors.

    Eli Lilly Co.

    Advanced Breast Cancer and Other Solid Tumors

    phase 1 other active

    1 trial

  23. A study of the PAN-KRAS inhibitor LY4066434 in participants with KRAS mutant solid tumors.

    Eli Lilly Co.

    Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor Metastatic Solid Tumor, PanKRAS.

    phase 1 other active

    1 trial

  24. A study to assess the pharmacokinetics, and glucodynamics of LY3209590 in participants with type 2 diabetes

    Eli Lilly Co.

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources